1388 related articles for article (PubMed ID: 19451442)
21. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib: new drug. Second-line treatment of kidney cancer: better evaluated than sunitinib.
Prescrire Int; 2007 Aug; 16(90):141-3. PubMed ID: 17724834
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib: a promising new targeted therapy for renal cell carcinoma.
Wood LS; Manchen B
Clin J Oncol Nurs; 2007 Oct; 11(5):649-56. PubMed ID: 17962173
[TBL] [Abstract][Full Text] [Related]
24. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.
Hutson TE; Bellmunt J; Porta C; Szczylik C; Staehler M; Nadel A; Anderson S; Bukowski R; Eisen T; Escudier B;
Eur J Cancer; 2010 Sep; 46(13):2432-40. PubMed ID: 20656473
[TBL] [Abstract][Full Text] [Related]
25. Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview.
Hutson TE
Expert Rev Anticancer Ther; 2007 Sep; 7(9):1193-202. PubMed ID: 17892420
[TBL] [Abstract][Full Text] [Related]
26. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
Procopio G; Verzoni E; Gevorgyan A; Mancin M; Pusceddu S; Catena L; Platania M; Guadalupi V; Martinetti A; Bajetta E
Oncology; 2007; 73(3-4):204-9. PubMed ID: 18418013
[TBL] [Abstract][Full Text] [Related]
27. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
Sternberg CN; Hawkins RE; Wagstaff J; Salman P; Mardiak J; Barrios CH; Zarba JJ; Gladkov OA; Lee E; Szczylik C; McCann L; Rubin SD; Chen M; Davis ID
Eur J Cancer; 2013 Apr; 49(6):1287-96. PubMed ID: 23321547
[TBL] [Abstract][Full Text] [Related]
28. One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients.
Kawashima A; Takayama H; Arai Y; Tanigawa G; Nin M; Kajikawa J; Imazu T; Kinoshita T; Yasunaga Y; Inoue H; Nishimura K; Takada S; Nishimura K; Tsujimura A; Nonomura N;
Eur J Cancer; 2011 Jul; 47(10):1521-6. PubMed ID: 21550799
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL
Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
[TBL] [Abstract][Full Text] [Related]
32. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors.
Song T; Zhang W; Wu Q; Kong D; Ma W
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1233-8. PubMed ID: 21941188
[TBL] [Abstract][Full Text] [Related]
33. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
Zhang T; Ding X; Wei D; Cheng P; Su X; Liu H; Wang D; Gao H
Anticancer Drugs; 2010 Mar; 21(3):326-32. PubMed ID: 20016366
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
35. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.
Rimassa L; Santoro A
Expert Rev Anticancer Ther; 2009 Jun; 9(6):739-45. PubMed ID: 19496710
[TBL] [Abstract][Full Text] [Related]
36. Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients.
Ueda T; Imamura Y; Komaru A; Fukasawa S; Sazuka T; Suyama T; Naya Y; Nihei N; Ichikawa T; Maruoka M
Int J Urol; 2010 Sep; 17(9):811-5. PubMed ID: 20649824
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy.
Vickers MM; Choueiri TK; Rogers M; Percy A; Finch D; Zama I; Cheng T; North S; Knox JJ; Kollmannsberger C; McDermott DF; Rini BI; Heng DY
Urology; 2010 Aug; 76(2):430-4. PubMed ID: 20223508
[TBL] [Abstract][Full Text] [Related]
38. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma.
O'Day S; Gonzalez R; Lawson D; Weber R; Hutchins L; Anderson C; Haddad J; Kong S; Williams A; Jacobson E
J Clin Oncol; 2009 Nov; 27(32):5452-8. PubMed ID: 19826135
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib for the treatment of unresectable hepatocellular carcinoma.
Kane RC; Farrell AT; Madabushi R; Booth B; Chattopadhyay S; Sridhara R; Justice R; Pazdur R
Oncologist; 2009 Jan; 14(1):95-100. PubMed ID: 19144678
[TBL] [Abstract][Full Text] [Related]
40. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
Hauschild A; Agarwala SS; Trefzer U; Hogg D; Robert C; Hersey P; Eggermont A; Grabbe S; Gonzalez R; Gille J; Peschel C; Schadendorf D; Garbe C; O'Day S; Daud A; White JM; Xia C; Patel K; Kirkwood JM; Keilholz U
J Clin Oncol; 2009 Jun; 27(17):2823-30. PubMed ID: 19349552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
